Omega-3 fatty acids

Evidence: limited

Solid as general nutrition and plausible for blunting soreness and inflammation, but the recovery signal is inconsistent and no performance or running-economy benefit has been shown. Food-first where you can.

Not medical advice

This is a general knowledge base, not medical or dietary advice. If you are injured, unwell or weighing up a supplement or a change to your diet, speak to a doctor, physiotherapist or registered dietitian who knows your situation.

The omega-3 fatty acids that matter for athletes are EPA and DHA, the long-chain fats found in oily fish and fish oil. Once supplemented, they are incorporated into muscle cell membranes, and this membrane change is the proposed basis for most of their claimed effects (Smith et al. 2011). They are best thought of first as a general-health nutrient and only second as a possible training aid: the case for the former is far stronger than for the latter.

The proposed mechanisms

The headline mechanism is anabolic. In a tightly controlled trial, eight weeks of fish oil did not raise resting muscle protein synthesis but it did amplify the synthesis response to feeding, alongside greater activation of the mTOR signalling pathway (Smith et al. 2011). That points to a supporting role in protein and recovery nutrition rather than a standalone effect, and the study was small and used an artificial nutrient infusion rather than ordinary meals, so it is suggestive rather than settled.

The second proposed use is recovery: blunting the muscle soreness (DOMS), muscle damage and inflammation that follow hard sessions. A 2024 systematic review of randomised trials found omega-3 reduced some markers of muscle damage, such as creatine kinase, and lowered the inflammatory marker IL-6 in several studies, but the effects were inconsistent and did not appear across all trials or all markers (Fernández-Lázaro et al. 2024). The broader and better-evidenced reason most people take EPA and DHA is cardiovascular and general health, and there is some signal for immune support, neither of which is specific to running.

The honest state of the evidence

The recovery picture is mixed and built mostly on small studies. The same review concluded there was no clear benefit to muscle function or sports performance, and importantly noted that most trials did not even measure participants’ baseline omega-3 status, which muddies any conclusion (Fernández-Lázaro et al. 2024). No reliable improvement in endurance performance or running economy has been demonstrated. So the verdict is modest: a plausible minor recovery aid, a sound general-health nutrient, but not a proven performance supplement, which is consistent with the wider finding that most supplements add little over a good diet (Maughan et al. 2018).

A note of caution sits alongside this. Where omega-3 reduces inflammation it overlaps with antioxidant supplements, and high-dose antioxidants can blunt the very training adaptations a runner is chasing; the inflammatory response to exercise is partly a signal, not just damage. The recovery case for omega-3 should be read with that tension in mind.

How to take it, and quality

Trials commonly use roughly 1 to 3 g per day of combined EPA and DHA, with around 2400 mg/day for about four to five weeks a frequently effective protocol (Fernández-Lázaro et al. 2024). The food-first option is two to three servings of oily fish a week (salmon, mackerel, sardines), which covers the general-health case without a capsule at all and should be the default. As with any supplement decision, weigh the thin performance evidence against the cost and the better-established health rationale.

On safety and anti-doping: fish oil is generally well tolerated, with fishy aftertaste and mild gastrointestinal upset the usual complaints, and oxidised, poor-quality oils are a real concern, so product quality matters. Competing athletes subject to testing should choose products carrying batch-tested “informed” certification, since unverified supplements carry a contamination risk (Maughan et al. 2018).